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(57) The present invention relates to a method for
the preparation of derivatives of dimethano-[1,3] dioxoc-
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IV. The present invention also relates to the derivatives
of fonnula II, III and IV obtained through the method de-
scribed, to pharmaceutical compositions comprising the
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Description
FIELD OF THE INVENTION
[0001] The present invention relates to a method for the preparation of dimethano-[1,3]dioxocino[6,5-d]pyrimidine-
spiro derivatives specially derivatives of Tetrodotoxin. The present invention also relates to the derivatives obtained
through the method described, to pharmaceutical compositions comprising the same and to their use as a medicament.
BACKGROUND OF THE INVENTION
[0002] In the present application the following numbering will be used (see figure 1, page 7497 in Sato, K.; Akai, S.;
Sugita, N.; Ohsawa, T.; Kogure, T.; Shoji, H.; Yoshimura, J. J. Org. Chem. 2005, 70, 7496-7504):
[0003] Tetrodotoxin (also abbreviated as "TTX" in the context of this application) or octahydro-12-(hydroxymethyl)- 2-
imino-5,9: 7,10a- dimethano- 10aH-[1,3]dioxocino [6,5-d] pyrimidine- 4,7,10,11,12-pentol, is a potent Sodium channel
blocker, indispensable tool for the study of neurobiology and physiology. Tetrodotoxin was first isolated in 1909 from
the ovaries of the puffer fish, and named after the puffer fish family "Tetraodontidae" Despite being a small molecule, it
has an extremely complex structure characterised by a dioxaadamantane skeleton, a guanidine residue at C2 which is
part of a hemiaminal at C4, and an orthoacid bridge at C10. As a result, TTX has 4 quaternary carbon atoms and 8
sterogenic centers.
[0004] It should also be noted that TTX is usually present as a mixture of inter alia two possible tautomers: an ortoester
and a hydroxylactone (see scheme 1). The ratio of both tautomers depends on the media in which TTX is present. 
[0005] For further discussion regarding tautomeric forms of TTX, reference is made to pages 32-34 of "Tetodotoxin,
saxitoxin, and the molecular biology of the sodium channel", Anals of The New York Academy of Science, Vol. 479,
Edited by C. Y. Kao and S. R. Levinson; 1986.
[0006] Tetrodotoxin blocks diffusion of sodium through the voltage dependent sodium channels, preventing depolari-
zation and propagation of action potentials in nerve cells. The TTX-Na Channel binding site is extremely tight (Kd = 10-10
nM). Therefore it is used in pharmacological studies related to sodium channel proteins.
[0007] Usually, TTX is extracted from marine organisms (e.g. JP 270719 Goto and Takahashi) although a number of
synthetic routes have been described (US 6,552,191, US 6,478,966, US 6,562,968 or US 2002/0086997). Tetrodotoxin
is a well known compound described for example in WO 02/22129 as systemically acting as analgesic. For one of the
many descriptions of TTX it is recommended to turn to e.g. Tu, Anthony (Ed.) Handbook of Natural Toxins, Vol. 3: Marine
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Toxins and Venoms, 1988, 185-210 as well as to Kao (1966), Pharmacol. Rev. 18:997 - 1049 and others.
[0008] In view of the potent activity as a sodium channel blocker there is an ongoing research effort regarding the
synthesis of derivatives of TTX. New TTX derivatives could lead to compounds with comparable pharmacological activity,
but without the inconveniencies of this potent neurotoxin. US 5,846,975 (included herein by reference) from column 3
line 40 to column 6 line 40, describes a general formula of known TTX derivatives. TTX derivatives are, for example,
anhydrotetrodotoxin, tetrodaminotoxin, methoxytetrodotoxin, ethoxytetrodotoxin, deoxytetrodotoxin and tetrodonic acid,
6 epitetrodotoxin, 11-deoxytetrodotoxin as well as the hemilactal type TTX derivatives (e.g. 4-epi- TTX, 6-epi- TTX, 11-de-
oxy- TTX, 4-epi-11-deoxy-TTX, TTX- 8-O-hemisuccinate, chiriquitoxin, 11-nor-TTX- 6 (S)-ol, 11-nor-TTX- 6 (R)-ol,
11-nor-TTX-6,6- diol, 11-oxo- TTX and TTX-11-carboxylic acid), the lactone type TTX derivatives (e.g. 6-epi- TTX (lactone),
11-deoxy-TTX (lactone), 11-nor-TTX- 6(S)-ol (lactone), 11-nor-TTX- 6 (R)-ol (lactone), 11-nor-TTX- 6,6-diol (lactone),
5-deoxy-TTX, 5,11-dideoxy- TTX, 4-epi- 5,11-didroxy- TTX, 1-hydroxy- 5,11-dideoxy- TTX, 5,6,11-trideoxy-TTX and 4-
epi- 5,6,11- trideoxy- TTX) and the 4,9- anhydro type TTX analogs (e.g. 4,9-anhydro- TTX, 4,9-anhydro- 6-epi- TTX, 4,9-an-
hydro- 11-deoxy- TTX, 4,9-anhydro-TTX-8-O-hemisuccinate, 4,9-anhydro- TTX- 11-O-hemisuccinate). The typical de-
rivatives of TTX possess only 1/8 to 1/40 of the toxicity of TTX in mice, based upon bioassay in mice. It has been observed
that these derivatives produce joint action, and do not interact adversely.
[0009] Woodward et. al. (Pure Appl. Chem. 1964, 9, 49-74), from now on "Woodward’s paper", describes two 6,11-
isopropylidine derivatives of TTX: 6,11-O- isopropylidene- 4,9-anhydrotetrodotoxin- hydrochloride and 4-O- Methyl-6,11-
O-isopropylidenetetrodotoxin-hydrochloride (Rajappa hydrochloride and Gougoutas hydrochloride, respectively):
[0010] Although Woodward’s paper does not specifically discloses the method for obtaining both compounds, a general
description of the method used is disclosed in page 37 of "Tetodotoxin, saxitoxin, and the molecular biology of the sodium
channel", Anals of The New York Academy of Science, Vol. 479, Edited by C. Y. Kao and S. R. Levinson; 1986. According
to the latest, Gougoutas hydrochloride was obtained by first bubbling HCl to a solution of anhydrous methanol/acetone
and then storing TTX in the resulting anhydrous solution of methanol/acetone/HCl at room temperature. Rajappa hy-
drochloride was obtained by first bubbling HCl to a solution of anhydrous acetone and then storing TTX in the resulting
anhydrous solution of acetone/HCl at room temperature, in the absence of methanol. Cristalographic data is provided
for Gougoutas hydrochloride.
[0011] The above method for obtaining Gougoutas hydrochloride is described in more detail in Nachman, R.J. Ph D
thesis, 1981, Stanford University, Standford, California (from now on, "Nachman’s thesis"). The process comprises
adding 10.15 mg (31.8P moles) of tetrodotoxin to a solution of 1.75 ml of anhydrous 0.3 N methanolic hydrogen chloride
and 1.00 ml of distilled acetone. The TTX quickly dissolved and the solution was stored 48 hours. The solution was then
stored for an additional 72 hours over methanol saturated with potassium hydroxide. The volume of solution had been
reduced by evaporation to 0.5 ml and was filled with crystals. The crystal suspension was centrifuged and the supernatant
was drawn off with a 50Pl syringe. The crystals were both washed with 0.15 ml of cold methanol and centrifuged a total
of three times to obtain 7.67 mg of crystalline gogoutas hydrochloride (65% yield).
SUMMARY OF THE INVENTION
[0012] As mentioned above, there is an ongoing research effort for providing TTX derivatives and prodrugs and
alternative synthetic approaches to said derivatives of TTX.
[0013] Thus, according to a first aspect, the present invention is directed to a process for the synthesis of a compound
of formula II as defined below comprising the step of reacting a compound of formula I as defined below, with a carbonyl
or boron reagent as defined below, in the presence of a substantially anhydrous acid solution which has been generated
in situ .
[0014] According to a further aspect, the present invention is directed to a process for the synthesis of a compound
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of formula III as defined below comprising the step of reacting a compound of formula I with said carbonyl or boron
reagent, in the presence of a substantially anhydrous acid solution which has been generated in situ.
[0015] According to a further aspect, the present invention is directed to a process for the synthesis of a compound
of formula IV as defined below comprising the step of reacting a compound of formula I with said carbonyl or boron
reagent, in the presence of a substantially anhydrous acid solution which has been generated in situ.
[0016] According to a further aspect, the present invention is directed to said compound of formula II or its tautomers
or enantiomers or solvates or salts or mixtures thereof.
[0017] According to a further aspect, the present invention is directed to said compound of formula III or its tautomers
or enantiomers or solvates or salts or mixtures thereof.
[0018] According to a further aspect, the present invention is directed to said compound of formula IV or its tautomers
or enantiomers or solvates or salts or mixtures thereof.
[0019] According to a further aspect, the present invention is directed to a pharmaceutical composition comprising
said compound of formula II, or a pharmaceutically acceptable salt or solvate or tautomer or enantiomer thereof, and at
least one pharmaceutically acceptable carrier.
[0020] According to a further aspect, the present invention is directed to a pharmaceutical composition comprising
said compound of formula III, or a pharmaceutically acceptable salt or solvate or tautomer or enantiomer thereof, and
at least one pharmaceutically acceptable carrier.
[0021] According to a further aspect, the present invention is directed to a pharmaceutical composition comprising
said compound of formula IV, or a pharmaceutically acceptable salt or solvate or tautomer or enantiomer thereof, and
at least one pharmaceutically acceptable carrier.
[0022] According to a further aspect, the present invention is directed to the use of said compound of formula II for
manufacturing a medicament for the treatment and/or prophylaxis of pain, especially cancer pain, cancer treatment
related pain, moderate to severe pain, and neuropathic pain; drug abuse and/or drug addiction, medicament abuse
and/or medicament addiction, preferably drug abuse and/or drug addiction; and nicotine addiction.
[0023] According to a further aspect, the present invention is directed to the use of said compound of formula III for
manufacturing a medicament for the treatment and/or prophylaxis of pain, especially cancer pain, cancer treatment
related pain, moderate to severe pain, and neuropathic pain; drug abuse and/or drug addiction, medicament abuse
and/or medicament addiction, preferably drug abuse and/or drug addiction; and nicotine addiction.
[0024] According to a further aspect, the present invention is directed to the use of said compound of formula IV for
manufacturing a medicament for the treatment and/or prophylaxis of pain, especially cancer pain, cancer treatment
related pain, moderate to severe pain, and neuropathic pain; drug abuse and/or drug addiction, medicament abuse
and/or medicament addiction, preferably drug abuse and/or drug addiction; and nicotine addiction.
BRIEF DESCRIPTION OF THE FIGURES
[0025]
FIGURE I is an HPLC chromatogram of an aliquot (time 8 days) of the preparation reaction of 6,11-O-isopropylidene-
4,9- anhydrotetrodotoxin hydrochloride (2) and 6,11-O-isopropylidene-4,9-anhydrotetrodotoxin- hydrochloride (3).
The arrows show the peaks assigned to compounds 2 and 3 (ratio [2:3] = 0.46) by means of their corresponding
mass spectra. See Example 1.
FIGURE 2 is a 1H- RMN (Methanol-d4) spectrum of a mixture of compounds 2 and 3 (ratio [2:3], aprox. 0.5; ratio
calculated by the proportion of the integrals corresponding to H(4) for compounds 2 and 3, respectively). Keys: #,
signal assigned to H(4) of compound 2; *, signal assigned to H (4) of compound 3. See Example 1.
FIGURE 3 is a mass spectrum of a mixture of compounds 2 and 3 (ratio [2: 3], aprox. 0.5; determinated from 1H-
RMN and HPLC). The arrows show the peaks assigned to compounds 2 and 3. See Example 1.
FIGURE 4 is a HPLC description of an aliquot of the formation reaction of the mixture of 2 and 3 at a time of 26
hours (t1) (The arrows show the peaks assigned to compounds 2 and 3 supported by their corresponding mass
spectra). See Example 1.
FIGURE 5 is a HPLC description of an aliquot of the formation reaction of the mixture of 2 and 3 at a time of 144
hours (t2) (The arrows show the peaks assigned to compounds 2 and 3 supported by their corresponding mass
spectra). See Example 1.
FIGURE 6 is a HPLC description of an aliquot of the formation reaction of the mixture of 2 and 3 at a time of 192
hours (t3) (The arrows show the peaks assigned to compounds 2 and 3 supported by their corresponding mass
spectra). See Example 1.
FIGURE 7 is a 1H- RMN (Methanol-d4) spectrum of 4-O-Methyl-6,11-O-isopropylidenetetrodotoxin-hydrochloride
(4). See Example 2.
FIGURE 8 is a Mass spectrum of compound 4. See Example 2.
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FIGURE 9 is an HPLC description of an aliquot of the formation reaction of the compound 4 at a time of 7 hours (t1)
(the arrows show the peaks assigned to compounds TTX (1), 2, 3 and 4 supported by their corresponding mass
spectra). See Example 2.
FIGURE 10 is an HPLC description of an aliquot of the formation reaction of the compound 4 at a time of 120 hours
(t2) (the arrows show the peaks assigned to compounds 2, 3 and 4 supported by their corresponding mass spectra).
See Example 2.
FIGURE 11 is an HPLC description of an aliquot of the formation reaction of the compound 4 at a time of 168 hours
(t3) (the arrows show the peaks assigned to compounds 2, 3 and 4 supported by their corresponding mass spectra).
See Example 2.
FIGURE 12 is an HPLC description of an aliquot of the formation reaction of the compound 4 at a time of 216 hours
(t4) (the arrows show the peaks assigned to compounds 2, 3 and 4 supported by their corresponding mass spectra).
See Example 2.
FIGURE 13 is an HPLC description of an aliquot of the formation reaction of the compound 4 at a time of 888 hours
(t5) (the arrows show the peaks assigned to compounds 2, 3 and 4 supported by their corresponding mass spectra).
See Example 2.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0026] It will be appreciated that for the purposes set out herein, the compounds of formula I, II, III or IV can be
optionally in the form of their racemate, pure stereoisomers, especially enantiomers or diastereomers or in the form of
mixtures of stereoisomers, especially enantiomers or diastereomers, in any suitable ratio; in neutral form, in the form of
an acid or base or in form of a salt, especially a pharmaceutically acceptable salt, or in form of a solvate, especially a
hydrate. The process of the invention does not usually involve a change in the spatial configuration of any of the
stereocenters of the molecule. Thus, if the starting material is a racemate, the product of the invention will usually be a
racemate of a compound of formula II, III or IV. However, it should be noted that partial or total epimerization of one or
more stereogenic centers is also possible.
[0027] In order to facilitate the comprehension of the present invention, the meanings of some terms and expressions
as used in the context of the invention are included herein.
[0028] "Heterocyclyl" refers to a stable 3- to 15- membered ring which consists of carbon atoms and from one to
five heteroatoms selected from the group consisting of nitrogen, oxygen, and sulphur, preferably a 5- to 10-membered
ring with one or more heteroatoms. For the purposes of this invention, the heterocycle may be a monocyclic, bicyclic or
tricyclic ring system, which may include fused ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl
radical may be optionally oxidised; the nitrogen atom may be optionally quatemized; and the heterocyclyl radical may
be partially or fully saturated or aromatic. Examples of such heterocycles include, but are not limited to, azepines,
benzimidazole, benzothiazole, furan, isothiazole, pyridine, imidazole, indole, piperidine, pyrrolidine, piperazine, purine,
quinoline, isoquinoline, quinoxaline, thiadiazole, tetrahydrofuran, phtalamide.
[0029] "Aryl" refers to an aromatic hydrocarbon radical with 6 to 20, preferably 6 to 10, carbon atoms, such as phenyl,
naphthyl or anthracyl.
[0030] "Aralkyl" refers to an aryl group linked to an alkyl group such as benzyl and phenethyl.
[0031] "Alkyl" refers to a straight or branched hydrocarbon chain radical consisting of carbon and hydrogen atoms,
containing no saturation, having 1-12, preferably one to six carbon atoms, and which is attached to the rest of the
molecule by a single bond, e. g., methyl, ethyl, n-propyl, i- propyl, n-butyl, t- butyl, n- pentyl, etc.
[0032] "Alkoxyl" refers to a radical of the formula -O-alkyl, -O-akenyl, -O-aryl or -O-aralkyl, wherein alkyl, alkenyl,
aryl and aralkyl are as previously defined, e. g., methoxy, ethoxy, propoxy, phenoxy, vinyl ethyl ether, benzyloxy, etc.
[0033] "Alkenyl" refers to a straight or branched hydrocarbon chain radical consisting of carbon and hydrogen atoms,
containing at least one unsaturation, having 1-12, preferably one to six carbon atoms, and which is attached to the rest
of the molecule by a single bond.
[0034] "Cycloalkenyl" refers to a carbocyclic ring having from 3 to 8 carbon atoms and at least one unsaturation.
[0035] "Cycloalkyl" refers to a saturated carbocyclic ring having from 3 to 8 carbon atoms.
[0036] All of the above groups (heterocyclyl, aryl, aralkyl, alkyl, alkoxyl, alkenyl, cycloalkenyl and cycloalkyl) may be
substituted or unsubstituted. References herein to substituted groups in the compounds of the present invention refer
to the specified moiety that may be substituted at one or more available positions by one or more suitable groups, e. g.,
halogen such as fluoro, chloro, bromo and iodo ; alkyl; aryl; protecting groups; cyano; hydroxyl; nitro; azido ; alkanoyl
such as a C1-6 alkanoyl group such as acyl and the like; carboxiamides of formula -CONH2, -CONHR’, -CONR’R",
wherein R’ and R" are independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted
cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted
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aryl, substituted or unsubstituted aralkyl or substituted or unsubstituted heterocyclyl; or R’ and R" together form a sub-
stituted or unsubstituted heterocycle, substituted or unsubstituted cycloalkyl or substituted or unsubstituted cycloalkenyl;
carboxylic acid (-COOH); carboxylate of formula -C (=O)-O- alkyl, wherein alkyl is as defined above; alkenyl and alkynyl
groups including groups having one or more unsaturated linkages and from 2 to about 12 carbon or from 2 to about 6
carbon atoms; alkoxy groups having one or more oxygen linkages and from 1 to about 12 carbon atoms or 1 to about
6 carbon atoms; aryloxy such as phenoxy ; alkylthio groups including those moieties having one or more thioether
linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms ; alkylsulfinyl groups including those
moieties having one or more sulfinyl linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms ;
alkylsulfonyl groups including those moieties having one or more sulfonyl linkages and from 1 to about 12 carbon atoms
or from 1 to about 6 carbon atoms ; aminoalkyl groups such as groups having one or more N atoms and from 1 to about
12 carbon atoms or from 1 to about 6 carbon atoms; carbocylic aryl having 6 or more carbons, particularly phenyl or
naphthyl and aralkyl such as benzyl. Unless otherwise indicated, an optionally substituted group may have a substituent
at each substitutable position of the group, and each substitution is independent of the other.
[0037] "Halogen" refers to fluoro (-F), chloro (-C 1), bromo (-Br) or iodo (-I).
[0038] "Protecting group" refers to a group that blocks an organic functional group and can be removed under
controlled conditions. Protecting groups, their relative reactivity and conditions under which they remain inert are known
to the skilled person. Reference is made to Greene and Wuts "Protective Groups in Organic Synthesis", John Wiley &
Sons, Inc., New York, 1999.
[0039] For example, "amino protecting group" refers to a group that blocks the -NH2 function for further reactions
and can be removed under controlled conditions. The amino protecting groups are well known in the art, representative
protecting groups are carbamates, e.g. carbamates of formula -C(=O) OR"’, amides, e.g. amides of formula -C (=O)R"’,
such as substituted or unsubstituted acetates or silyl moieties of formula -Si(R"’)3, wherein R"’ represents a group
selected from the group consisting of substituted of unsubstituted alkyl, substituted of unsubstituted alkenyl, substituted
of unsubstituted alkynyl, substituted of unsubstituted aryl and substituted of unsubstituted aralkyl. Also different alkyl
moeties may serve as amino protecting groups. Said alkyl groups may optionally be substituted by one or more substit-
uents such as halo, hydroxy, alkoxy, alkyloxymethyl ethers, carboxy, cyano, carbonyl, acyl, alkoxycarbonyl, amino, nitro,
mercapto and alkylthio. Additional examples of amino protecting groups can be found in reference books such as Greene
and Wuts’ "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, 1999.
[0040] Further, "hydroxyl protecting group" refers to a group that blocks the -OH function for further reactions and
can be removed under controlled conditions. The hydroxyl protecting groups are well known in the art, representative
protecting groups are: 
- silyl ethers of formula -Si (R"’)3, such as trimethylsilyl ether (also represented as "TMS"), triethylsilyl ether, tert-
butyldimethylsilyl ether (also represented as "TBDMSO"), tert-butyldiphenylsilyl ether, tri- isopropylsilyl ether, diethyl-
isopropylsilyl ether, thexyldimethylsilyl ether, triphenylsilyl ether, di-tert-butylmethylsilyl ether, and other bifunctional
silyl protecting groups such as 1,1,3,3-tetraisopropyldisiloxane- 1,3-diyl;
- alkyl ethers of formula -R"’, such as methyl ether, tert-butyl ether, benzyl ether, p-methoxybenzyl ether , 3,4- dimeth-
oxybenzyl ether, trityl ether; allyl ether;
- alkoxymethyl ethers of formula -CH2-O- R"’, such as methoxymethyl ether, 2-methoxyethoxymethyl ether, benzy-
loxymethyl ether, p- methoxybenzyloxymethyl ether, 2-(trimethylsilyl)ethoxymethyl ether. The oxygen atom may be
replaced by a sulphur atom to form an alkylthiomethyl ether of formula -CH2-S-R’, such as methylthiomethyl ether.
Tetrahydropyranyl and related ethers are also commonly used as hydroxyl protecting groups;
- esters of formula -C (=O) R’", such as acetate ester, benzoate ester; pivalate ester; methoxyacetate ester; chloroa-
cetate ester; levulinate ester;
- carbonates of formula -C (=O)-O- R"’, such as benzyl carbonate, p-nitrobenzyl carbonate, tert-butyl carbonate, 2,2,2-
trichloroethyl carbonate, 2-(trimethylsilyl)ethyl carbonate, allyl carbonate; or
- sulphates such as SO3py.
[0041] In all the above formula R’ is as defined above.
[0042] Additional examples of hydroxyl protecting groups can be found in reference books such as Greene and Wuts’
"Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, 1999.
[0043] The term "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically
tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the
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like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved
by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopoeia or other generally
recognized pharmacopoeia for use in animals, and more particularly in humans.
[0044] The term "salt" refers to the compounds of the present invention having a ionic form or a charge and are
coupled to a counter ion (cation or anion), or are in solution. Complexes of the active compounds of formula II, III or IV
are also included, particularly ionic complexes between the compounds of formula II, III or IV and other molecules. The
term salt as used herein also encompasses Zwitterion forms, that is, forms having both, acidic and basic groups in the
same molecule. Thus, when suitable, they can be represented as neutral molecules or diionic forms. For example, TTX
can be represented as the neutral form of diionic form: 
Also, the compounds of formula II and IV of the invention may be present as Zwitterion or as neutral forms.
[0045] The term "pharmaceutically acceptable salts" refers to any pharmaceutically acceptable salt, which, upon
administration to the recipient is capable of providing (directly or indirectly) the compounds as described herein.
[0046] For instance, pharmaceutically acceptable salts of compounds provided herein may be acid addition salts,
base addition salts or metallic salts, and they can be synthesized from the parent compound which contains a basic or
an acidic moiety by conventional chemical methods. Generally, such salts are, for example, prepared by reacting the
free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in
an organic solvent or in a mixture of the two. Generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol
or acetonitrile are preferred. Examples of the acid addition salts include mineral acid addition salts such as, for example,
hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate, phosphate, and organic acid addition salts such as, for
example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulphonate and
p-toluenesulphonate. Examples of the alkali addition salts include inorganic salts such as, for example, ammonium, and
organic alkali salts such as, for example, ethylenediamine, ethanolamine, N,N-dialkylenethanolamine, triethanolamine,
glucamine and basic aminoacids salts. Examples of the metallic salts include, for example, sodium, potassium, calcium,
magnesium, aluminium and lithium salts.
[0047] The term "carrier" refers to a diluent, adjuvant, excipient, and/or vehicle with which the active ingredient is
administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum,
animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or
aqueous saline solution, or dextrose or glycerol solutions are preferably employed as carriers, particularly for injectable
solutions. Suitable pharmaceutical carriers are described in "Remington’s Pharmaceutical Sciences" by E.W. Martin.
[0048] The term "solvate" according to this invention is to be understood as meaning any form of the active compound
according to the invention which has another molecule (most likely a polar solvent) attached to it via non-covalent
bonding. Examples of solvates include hydrates and alcoholates, e.g. methanolate.
Process for the synthesis of compounds of formula II
[0049] In the continuous research effort of the inventors with regard to TTX, its derivatives or prodrugs thereof, the
synthesis of a compound of formula II was attempted. Different experiments where performed with different acids.
Surprisingly, in situ generation of the acid under anhydrous conditions was effective for obtaining the desired compound
of formula II.
[0050] Thus, as mentioned above, the first aspect of the present invention is a process (hereinafter referred to as
process of the invention) for the synthesis of a compound of formula II:
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wherein
R1 is selected from the group consisting of -H, -OH, -OC (=O)Ra, -ORa, alkyl,-NH2, -NHRb and -NRbRc, wherein Ra,
Rb and Rc are independently selected from an alkyl group;
R2 and R3 are independently selected from the group consisting of -H, -OH and-OC(=O) Ra, -ORb, wherein Ra and
Rb are as previously defined;
R4 and R5 are independently selected from the group consisting of -H and amino protecting group;
R6 is selected from the group consisting of -H, a negative charge and a hydroxyl protecting group;
W is selected from the group consisting ofNH, ⊕NH2, O and S; and
Z is selected from the group consisting of
(R7)(R8)C< wherein R7 and R8 are each independently selected from the group consisting of alkyl, cycloalkyl,
alkenyl, cycloalkenyl, alcoxyl, heterocyclyl, aryl and aralkyl; or R7 and R8 together form a group selected from
the group consisting of cycloalkyl, heterocyclyl and cycloalkenyl; and -(R9)B<, wherein R9 is selected from the
group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocyclyl, aryl and aralkyl;
or its salts, in particular pharmaceutically acceptable salts, or tautomers, solvates or enantiomers thereof;
comprising the step of reacting a compound of formula I
wherein
R1, R2, R3, R4, R5, R6 and W are as defined in formula II;
with a carbonyl or boron reagent selected from the group consisting of
- a carbonyl containing molecule of formula (R7)(R8)C=O or its hydrates or alkyl or aryl acetals or hemiacetals, wherein
R7 and R8 are as previously defined;
- a boron derivative of formula R9B(OR10)2, wherein R10 are both independently selected from the group consisting
of -H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocyclyl, aryl and aralkyl;
- a boron derivative of formula R9B=O; and
- a boron derivative of formula
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wherein R9 is as defined above;
in the presence of a substantially anhydrous acid solution which has been generated in situ.
[0051] The process of the invention yields the compounds of formula II in good yield. For purposes of the present
invention, "generating in situ a substantially anhydrous acid solution" or "a substantially anhydrous acid solution which
has been generated in situ" makes reference to the methods known by the skilled person to generate acids in the reaction
media from appropriate precursors of the acid.
[0052] In one embodiment said methods involve the addition of an alcohol and of an acid precursor which react to
yield the corresponding acid.
[0053] According to a preferred embodiment, said alcohol is an alcohol of formula R11OH, wherein R11 is selected
from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocyclyl, aryl and aralkyl.
[0054] According to an embodiment, said acid precursor is selected from the group consisting of
- an acyl halide of formula R12COX, wherein
X is selected from the group consisting of F, Cl, Br or I; and
R12 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocyclyl, aryl and aralkyl;
- an acid anhydride of formula R12C(=O) O(O=) CR12, wherein each of R12 can be the same or different as defined
above; and
- an acid anhydride of formula R13 (O=)2SOS(=O)2R13, wherein each of R13 are independently selected from the
group consisting of alkyl, preferably halogen substituted alkyl, aryl and aralkyl.
[0055] For economy reasons, R11 is usually an alkyl group, preferably a C1-C6 alkyl, such as methyl or ethyl. However,
the skilled person is aware that any alcohol capable of reacting with a given acyl halide or acid anhydride is suitable for
the purposes of the present invention, i. e. generating in situ a substantially anhydrous acid solution.
[0056] Also, for economy reasons R12 or R13 are usually an alkyl group, preferably a C1-C6 alkyl, such as methyl or
ethyl. Also, the skilled person is aware that any acid precursor capable of reacting with a given alcohol is suitable for
the purposes of the present invention. According to an alternative embodiment, R13 is -CF3 or p- tolyl, so that the anhydride
of formula R13(O=)2SOS (=O)2R13 is trifluoromethanesulfonic anhydride or p-tolylsulfonic anhydride respectively.
[0057] The pH usually achieved by the process of the invention is preferably below 4.5, more preferably bellow 4 and
more preferably below 3.
[0058] For the purposes of the present invention "substantially anhydrous" refers to solutions or reaction media sub-
stantially free of water. The skilled person is aware of the precautions needed in each case to obtain a substantially
anhydrous reaction media. It is also immediately apparent to the skilled person, that it is almost impossible to generate
a reaction media which is completely free of water. The amount in which water is present depends to a large extend of
the material available in the moment of performing the reaction. Further, the presence of small amounts of water does
not completely hamper the reaction, but lowers the yields of the desired compounds of formula II, III or IV obtained.
[0059] It is also evident to the skilled person that removing water generated during the reaction is advantageous.
Means for removing water from reaction media are known in the art, e.g. Dean-Stark apparatus or molecular sieves.
[0060] As a result of the process of the invention, the hydroxyl groups on C6 and C11 are protected (group "Z" in the
compounds of formula II). There are a number of protecting groups for 1,2-diols described in the art. Cyclic acetals are
widely used. The most common reagent used is the appropriate carbonyl containing molecule. However, it will be
immediately apparent to the skilled person the possibility of using equivalents or precursors (synthetic equivalents) of
a carbonyl containing molecule in order to effect the reaction. Synthetic equivalents are functional groups used in organic
synthesis which have a similar structure and perform substantially the same function. The present patent application
encompasses all such synthetic equivalents or equivalents of the carbonyl group. For example, it would be obvious to
the skilled person the use of dialkylacetals as synthetic equivalents of ketones. The skilled person can easily find in the
literature which groups are equivalents of the carbonyl group for the purposes of process of the invention;  for example,
see Greene and Wuts’ "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, 1999. Some
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examples of synthetic equivalents of a carbonyl group are compounds having the following formulas:
wherein R7 and R8 have the same meaning as above, and R is usually an alkyl group, although it may also be selected
from the group consisting of aryl, aralkyl, heterocyclyl, alkenyl, cycloalkyl or cycloalkenyl, or both R groups together form
a cycloalkyl or cycloalkenyl group. The skilled person is aware these are the most common equivalents of a carbonyl
containing molecule, although other equivalents are well known in the art, such as hydrates, or hemiacetals or orthoacetals
or imines or enamines. Thioacetals are also commonly used as carbonyl equivalents.
[0061] According to a preferred embodiment, (R7)(R8)C=O is selected from the group consisting of formaldehyde,
acetaldehyde, 2,2-dimethylpropylaldehyde, 3,3-dimethylbutirylaldehyde, 3,3-dimethyl-2-butanone, 4’- methoxyace-
tophenone, acrolein, acetone, ethyl acetate, methyl acetate, ethyl formate, methyl formate and 3H- Isobenzofuran-1-
one, or the hydrates or alkyl or aryl acetals or hemiacetals thereof. According to a preferred embodiment, (R7)(R8)C=O
is acetone.
[0062] The boron reagents of the invention are commercially available or readily prepared in different forms. Thus,
depending on the nature of the specific boron reagent it may be in the form of a compound of formula R9B(OR10)2, a
compound of formula R9B=O or a compound of formula
wherein R9 is as previously defined.
[0063] According to further embodiment, the compound of formula R9B=O is selected from the group consisting of
butylboronic acid and phenylboronic acid.
[0064] The compounds of formula I used as starting materials for the reaction may be synthesized by processes known
in the art. As mentioned above US 6,552,191, US 6,478,966, US 6,562,968 or US 2002/0086997 describe different
synthesis of TTX. Also, European patent application EP05077580.8, in the name of the applicant, discloses the synthesis
of a compound of formula I. All the previous references are herein incorporated by reference.
[0065] It is known that the compounds of formula I (TTX and its derivatives) in solution, usually represented as an
orthoester, are in equilibrium with the corresponding hydroxylactone (See scheme 2). The relative proportion of each
one depends on the nature of each derivative and on the physico-chemical conditions of the solution (temperature,
polarity of the solvent, pH, etc). Therefore, it can be considered that representing TTX as an orthoester or as a hydrox-
ylactone is equivalent. 
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[0066] In the same way as above, the compounds of formula II wherein R6 is hydrogen or a negative charge, may be
present as an equilibrium of two tautomeric forms as shown in scheme 3:
wherein R1, R2, R3, R4, R5, Z and W are as defined above for the compounds of formula II. Thus, for the purposes of
the present invention the representation of a compound of formula II as an orthoester is equivalent to the representation
as a hydroxylactone.
Process for the synthesis of compounds of formula III and IV
[0067] As mentioned above, in the process of the invention it is possible to obtain the compounds of formula II.
However, following the same principle it is also possible to carry out the reaction so as to yield the compounds of formula
III and IV described hereinafter.
[0068] Thus, according to a further aspect, the present invention is directed to a process for the synthesis of a compound
of formula III
wherein
R2, R4, R5 and Z are as defined in claim 1;
R1 is alcoxyl; and
W is selected from the group consisting of -NH, O and S;
or its salts, in particular pharmaceutically acceptable salts, or tautomers, solvates or enantiomers thereof;
comprising the step of reacting a compound of formula I, wherein R3 is -OH, with a carbonyl or boron reagent of formula
(R7)(R8)C=O or of formula R9B(OR10)2, or of formula R9B=O or of formula
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wherein the compound of formula I and the carbonyl or boron reagent are as defined in claim 1 in the presence of a
substantially anhydrous acid solution which has been generated in situ and an alcohol, said alcohol being in excess with
regard to the carbonyl or boron reagent.
[0069] In the same way as explained above, the compounds of formula III may be present as an equilibrium of two
tautomeric forms as shown in scheme 4:
wherein R1, R2, R4, R5, Z and W are as defined above for the compounds of formula III. Thus, for the purposes of the
present invention the representation of a compound of formula III as an orthoester is equivalent to the representation
as a hydroxylactone.
[0070] According to a further aspect, the present invention is directed to a process for the synthesis of a compound
of formula IV
wherein
R2, R4, R5, R6 and Z are as defined in claim 1; and
W is selected from the group consisting of -NH, O and S;
or its salts, in particular pharmaceutically acceptable salts, or tautomers, solvates or enantiomers thereof;
comprising the step of reacting a compound of formula I, wherein R3 is -OH, with a carbonyl or boron reagent of formula
(R7)(R8)C=O or of formula R9B(OR10)2 or of formula R9B=O or of formula
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wherein the compound of formula I and the carbonyl or boron reagent are as defined in claim 1, in the presence of a
substantially anhydrous acid solution which has been generated in situ and an alcohol, said alcohol being in equimolar
ratio with regard to the carbonyl or boron reagent.
[0071] In the same way as above, the compounds of formula IV wherein R6 is hydrogen or a negative charge, may
be present as an equilibrium of two tautomeric forms as shown in scheme 5:
wherein R2, R4, R5, Z and W are as defined above for the compounds of formula IV. Thus, for the purposes of the present
invention the representation of a compound of formula IV as an orthoester is equivalent to the representation as a
hydroxylactone.
[0072] Of course, the skilled person is aware that the term "equimolar" ratio stands for the situation in which two or
more compounds are in the same molar amount. However, one of the compounds may be added in slightly different
amounts for different reasons. For example, one of the compounds could be more stable than the other, and, in order
to achieve the same effective amount of both in the reaction media, it is possible to add less amounts of the more stable
compound. Differences may also arise due to the intrinsic limits of the measuring devices commonly used in a laboratory.
Therefore, for the purposes of the invention, the term "equimolar" also encompasses small variations in the molar
proportions of the components.
[0073] In the process for the synthesis of the compound of formula III and in the process for the synthesis of a compound
of formula IV, the alcohol and the precursor of the acid have a function which is similar to that performed in the case of
the synthesis of the compounds of formula II. Therefore, according to an embodiment of the invention, said alcohol is
an alcohol of formula R11OH, wherein R11 is selected from alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocyclyl, aryl and
aralkyl, preferably C1-C6 alkyl.
[0074] According to a further embodiment, the compound of formula III or IV obtained is in the form of a salt, preferably
a salt of and acid selected from the group consisting of XH, R12C(=O) OH and R13 (O=)2SOH, wherein X, R12 and R13
are as defined above. Thus, said salts may be a result of the acid generated during the process of the invention. However,
different salts may be generated through a salt exchange reaction by dissolving the compound in a suitable solvent in
the presence of an excess of desired ion.
[0075] Thus, following a similar process it is possible to obtain compounds of formula II, III or IV from said compound
of formula I. There are essentially three possible versions of the reaction.
a) Generation in situ of the substantially anhydrous acid solution can be performed regardless of the nature of the
acid precursor. As explained below and in the examples, the reaction time may be controlled in order to either obtain
the compounds of II or the compounds of formula III or IV.
b) On the other hand, when an alcohol and a suitable acid precursor are used for generating in situ the substantially
anhydrous acid solution, but the alcohol is in equimolar ratio with regard to the acid precursor, the resulting compound
EP 1 882 692 A1
14
5
10
15
20
25
30
35
40
45
50
55
is a compound of formula II or a compound of formula IV. According to an embodiment of the invention, short reaction
times yield the compound of formula II as the major product of the reaction. The compound of formula II may act as
an intermediate towards the compounds of formula III and IV. Therefore, if the reaction is left sufficient time, the
major product will be the compound of formula IV. See scheme 6. For further discussion, see Example 1.
c) When an alcohol and a suitable acid precursor are used for generating in situ the substantially anhydrous acid
solution and the alcohol is in excess with regard to the acid precursor, the resulting compound is a compound of
formula II or a compound of formula III. In a similar way, according to an embodiment of the invention short reaction
times yield the compound of formula II as the major product of the reaction. If the reaction is left sufficient time, the
major product will be the compound of formula III. See scheme 7. For further discussion, see Example 2.
[0076] According to an embodiment of the invention, the reaction time of the process of the invention is less than 100
hours, preferably less than 50 hours, more preferably less than 40 hours, more preferably less than 30 hours, more
preferably less than 25 hours.
[0077] On the other hand, according to an embodiment of the invention, the time needed to complete the reaction and
obtain either the compound of formula III or the compound of formula IV as major product is more than 5 hours, preferably
more than 10 hours, more preferably more than 20 hours, more preferably more than 50 hours, more preferably more
than 100 hours. The time needed to complete the reaction will depend on various factors such as the nature of the
reagents or the reaction temperature.
[0078] Further, according to the experiments performed by the inventors, the compound of formula IV is the intermediate
to the compound of formula III (see Example 2). That is, if the reaction media contains no free alcohol and the reaction
is left to stand sufficient time, the compound of formula IV is formed. Under the same conditions, but having an excess
of alcohol, the reaction begins forming large amounts of the corresponding compound of formula II and small amounts
of the compound of formula IV. HPLC shows that the amount of the compound of formula IV remains essentially constant
through time, while the amount of the compound of formula II decreases and the amount of the compound of formula
III increases.
[0079] Thus it is possible to transform the isolated compound of formula IV into a compound of formula III. According
to an embodiment of the invention, the compound of formula IV is further transformed into a compound of formula III,
by further contacting said compound of formula IV with an alcohol.
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Transformation of compounds of formula II, III and IV
[0080] The compounds of the invention may be further manipulated. For example, the removal from the compounds
of the invention of the Z group yields compounds having free hydroxyl groups on C6 and C11. For methods for the
removal of the Z group, reference is made to Greene and Wuts’ "Protective Groups in Organic Synthesis", John Wiley
& Sons, Inc., New York, 1999. In the case of the compounds of formula III the overall result is the selective introduction
of an alkoxyl group on the C4 position.
[0081] Further transformations may include protection/deprotection reactions of other positions of the compounds of
the invention, e.g. protection/deprotection reactions on the different functionalities on positions 1, 2 , 3, 5, 8 and/or 9;
or, where possible, hydroxyl inversion (e.g. Mitsunobu reaction).
Compounds of formula II, III and IV
[0082] A further aspect of the present invention is a compound of formula II as defined above. According to a preferred
embodiment R1 is -OH. According to a further embodiment R1 is -H or -OAc. As mentioned above, the process of the
invention is also suitable to synthesize compounds of formula III and IV.
[0083] Thus, a further aspect of the invention is a compound of formula III as defined above with the proviso it is not
6,11- O-isopropylidene-4,9-anhydrotetrodotoxin- hydrochloride (Rajappa hydrochloride).
[0084] A further aspect of the invention is a compound of formula IV as defined above with the proviso it is not 4-O-
Methyl-6,11- O-isopropylidenetetrodotoxin-hydrochloride (Gougoutas hydrochloride).
[0085] According to a preferred embodiment, R2 and R3 are -OH in the compounds of formula II, III and IV. According
to further embodiment R2 and R3 are independently selected from -H or -OAc in the compounds of formula II, III and IV.
[0086] According to a preferred embodiment, R7 and R8 are both -H, methyl; or R7 is -H and R8 is selected from the
group consisting of methyl, t-butyl, 2,2- dimethylpropyl, vinyl, methoxy and ethoxy; or R7 is methyl and R8 is selected
from the group consisting of t-butyl, 4’-methoxyphenyl, ethoxy and methoxy.
Uses of the compounds of formula II, III and IV and pharmaceutical compositions comprising the same
[0087] A further aspect of the present invention is a pharmaceutical composition comprising a compound of formula
II as defined above or a pharmaceutically acceptable salt or solvate or tautomer or enantiomer thereof, and at least one
pharmaceutically acceptable carrier.
[0088] A further aspect of the present invention is a pharmaceutical composition comprising a compound of formula
III as defined above, or a pharmaceutically acceptable salt or solvate or tautomer or enantiomer thereof, and at least
one pharmaceutically acceptable carrier.
[0089] The compounds of formula III, depending on their nature, readily sublimate under reaction conditions. Therefore,
according to an embodiment of the invention, the pharmaceutical composition comprising a compound of formula III is
pressurised inhalators (solution, suspension, emulsion, etc.); inhalation powders (hard capsule); pre-dispensed inhalation
powders; inhalation vapours (powder, capsule, solution, tablet, ointment, liquid, etc.) or inhalation gases.
[0090] A further aspect of the present invention is a pharmaceutical composition comprising a compound of formula
IV as defined above, or a pharmaceutically acceptable salt or solvate or tautomer or enantiomer thereof, and at least
one pharmaceutically acceptable carrier.
[0091] The above will be referred to as the "pharmaceutical compositions of the invention".
[0092] For its administration to a subject, such as a mammal, e.g., a human, in need of treatment, the pharmaceutical
compositions of the invention may be administered by any appropriate route (via), such as, oral (e.g., oral, sublingual,
etc.), parenteral (e.g., subcutaneous, intramuscular, intravenous, intramuscular, etc.), rectal, nasal, topical, ophtalmic,
etc.
[0093] The carriers (as defined previously in the present patent application) necessary to manufacture the desired
pharmaceutical form of administration of the pharmaceutical compositions of the invention will depend, among other
factors, on the elected administration pharmaceutical form. Said pharmaceutical forms of administration of the pharma-
ceutical composition will be manufactured according to conventional methods known by the skilled person in the art. A
review of different active ingredient administration methods and excipients to be used and processes for producing them
can be found in "Tratado de Farmacia Galénica", C. Faulí i Trillo, Luzán 5, S.A. de Ediciones, 1993.
[0094] The percentage of the compound of formula I in the pharmaceutical composition will be different depending
on a number of factors, such as the administration form.
[0095] In a particular embodiment, the pharmaceutical compositions of the invention comprise, as active ingredient,
at least one compound of formula II, III or IV in a therapeutically effective amount. In the sense used in this description,
the expression "therapeutically effective amount" refers to the quantity of active ingredient calculated to produce the
desired effect, and will generally be determined, among other reasons, by the own features of the active ingredient used
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and the therapeutic effect to be obtained. In a particular embodiment, the dose of active ingredient administered to a
subject in need of treatment for the treatment and/or prophylaxis of the conditions is within the range of 10-4 to 103 mg/kg
of body weight, preferably 10-1 to 102 mg/kg of body weight.
[0096] A further aspect of the present invention is the use of a compound of formula II as described above for manu-
facturing a medicament for the treatment and/or prophylaxis of pain, especially cancer pain, cancer treatment related
pain, moderate to severe pain, and neuropathic pain; drug abuse and/or drug addiction, medicament abuse and/or
medicament addiction, preferably drug abuse and/or drug addiction; and nicotine addiction
[0097] A further aspect of the present invention is the use of a compound of formula III as described above for
manufacturing a medicament for the treatment and/or prophylaxis of pain, especially cancer pain, cancer treatment
related pain, moderate to severe pain, and neuropathic pain; drug abuse and/or drug addiction, medicament abuse
and/or medicament addiction, preferably drug abuse and/or drug addiction; and nicotine addiction.
[0098] A further aspect of the present invention is the use of a compound of formula IV as described above for
manufacturing a medicament for the treatment and/or prophylaxis of pain, especially cancer pain, cancer treatment
related pain, moderate to severe pain, and neuropathic pain; drug abuse and/or drug addiction, medicament abuse
and/or medicament addiction, preferably drug abuse and/or drug addiction; and nicotine addiction.
[0099] The above will be referred to as "use of the compounds of the invention".
[0100] Pain can originate for many reasons. A familiar cause is trauma, such as a sprain or muscle injury or broken
bone, or from surgery. Pain due to inflammation, such as a toothache, is also familiar to many. Headache is a common
experience and arises often for unknown reasons. Cancer patients may have pain for a variety of reasons. It may be
due to the effects of the cancer itself, or it could result from treatment methods, such as chemotherapy or surgery. For
example, after surgery a person feels pain as a result of the operation itself. Not all people with cancer have pain, and
those who do are not in pain all the time.
[0101] A preferred embodiment is the use of the compounds of the invention for cancer pain or cancer treatment
related pain.
[0102] A preferred embodiment is the use of the compounds of the invention for neuropathic pain.
[0103] "Neuropathic pain" is defined by the IASP as "pain initiated or caused by a primary lesion or dysfunction in the
nervous system" (IASP, Classification of chronic pain, 2nd Edition, IASP Press (2002), 210). For the purpose of this
invention included under this heading or to be treated as synonymous is "Neurogenic Pain" which is defined by the IASP
as "pain initiated or caused by a primary lesion, dysfunction or transitory perturbation in the peripheral or central nervous
system".
[0104] In a preferred embodiment of the use according to the invention the neuropathic pain is central pain.
[0105] According to the IASP "central pain" is defined as "a pain initiated or caused by a primary lesion or dysfunction
in the central nervous system" (IASP, Classification of chronic pain, 2nd Edition, IASP Press (2002), 211).
[0106] In another embodiment of the use according to the invention the neuropathic pain is peripheral neuropathic
pain or peripheral neurogenic pain.
[0107] According to the IASP "Peripheral neuropathic pain" is defined by the IASP as "pain initiated or caused by a
primary lesion or dysfunction in the peripheral nervous system" and "Peripheral neurogenic pain" as "pain initiated or
caused by a primary lesion, dysfunction or transitory perturbation in the peripheral nervous system" (IASP, Classification
of chronic pain, 2nd Edition, IASP Press (2002), 213).
[0108] In another preferred embodiment of the use according to the invention the neuropathic pain is allodynia.
[0109] According to the IASP "allodynia" is defined as "a pain due to a stimulus which does not normally provoke pain"
(IASP, Classification of chronic pain, 2nd Edition, IASP Press (2002), 210).
[0110] In another preferred embodiment of the use according to the invention the neuropathic pain is causalgia.
[0111] According to the IASP "causalgia" is defined as "a syndrome of sustained burning pain, allodynia and hyperpathia
after a traumatic nerve lesion, often combined with vasomotor and sudomotor dysfunction and later trophic changes"
(IASP, Classification of chronic pain, 2nd Edition, IASP Press (2002), 210).
[0112] In another preferred embodiment of the use according to the invention the neuropathic pain is hyperalgesia.
[0113] According to the IASP "hyperalgesia" is defined as "an increased response to a stimulus which is normally
painful (IASP, Classification of chronic pain, 2nd Edition, IASP Press (2002), 211).
[0114] In another preferred embodiment of the use according to the invention the neuropathic pain is hyperesthesia.
[0115] According to the IASP "hyperesthesia" is defined as "increased sensitivity to stimulation, excluding the senses"
(IASP, Classification of chronic pain, 2nd Edition, IASP Press (2002), 211).
[0116] In another preferred embodiment of the use according to the invention the neuropathic pain is hyperpathia.
[0117] According to the IASP "hyperpathia" is defined as "a painful syndrome characterized by an abnormally painful
reaction to a stimulus, especially a repetitive stimulus, as well as an increased threshold" (IASP, Classification of chronic
pain, 2nd Edition, IASP Press (2002), 212).
[0118] The IASP draws the following difference between "allodynia", "hyperalgesia" and "hyperpathia" (IASP, Classi-
fication of chronic pain, 2nd Edition, IASP Press (2002), 212): 
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[0119] In another preferred embodiment of the use according to the invention the neuropathic pain is neuralgia.
[0120] According to the IASP "neuralgia" is defined as "Pain in the distribution of a nerve or nerves" (IASP, Classification
of chronic pain, 2nd Edition, IASP Press (2002), 212).
[0121] In another preferred embodiment of the use according to the invention the neuropathic pain is neuritis.
[0122] According to the IASP "neuritis" is defined as "Inflammation of a nerve or nerves" (IASP, Classification of chronic
pain, 2nd Edition, IASP Press (2002), 212).
[0123] In another preferred embodiment of the use according to the invention the neuropathic pain is neuropathy.
[0124] According to the IASP "neuropathy" is defined as "a disturbance of function or pathological change in a nerve:
in one nerve mononeuropathy, in several nerves mononeuropthy multiplex, if diffuse and bilateral, polyneuropathy"
(IASP, Classification of chronic pain, 2nd Edition, IASP Press (2002), 212).
[0125] Medicaments/drugs, which are frequently the subject of misuse (leading often to addiction) include opioids,
especially morphine, barbiturates, cannabis, cocaine, amphetamines, phencyclidine, hallucinogens and benzodi-
azepines.
[0126] A preferred embodiment is the use of the compounds of the invention for the manufacture of a medicament for
the treatment of drug abuse and/or drug addiction, medicament abuse and/or medicament addiction, preferably drug
abuse and/or drug addiction.
[0127] A preferred embodiment is the use of the compounds of the invention for the manufacture of a medicament for
the treatment of nicotine addiction.
[0128] The term "treatment" or "to treat" in the context of this specification means administration of a compound or
formulation according to the invention to prevent, ameliorate or eliminate one or more symptoms associated with pain,
de-addiction from the drug/medicament, or de-addiction from nicotine. Such symptoms can arise from withdrawal, or
can be associated with relapse behavior, such as a craving of a subject for the drug/medicament. "Treatment" also
encompasses preventing, ameliorating or eliminating the physiological sequelae of removal of the drug/medicament
from an addicted subject that may cause the exhibited symptoms perceived by the subject. "Treatment" also encompasses
a reduction in the amount of the drug/ medicament that is consumed by a subject.
[0129] Furthermore, the terms "to treat" or "treatment" according to this invention include the treatment of symptoms
of de-addiction; nicotine, drug and/or medicament dependency; nicotine, drug and/or medicament withdrawal, especially
certain subtypes of de-addiction, drug dependency or nicotine withdrawal; the treatment of the consequences causing
the symptoms, and the prevention or prophylaxis causing the symptoms of de-addiction, or nicotine withdrawal, as well
as the prevention or the prophylaxis of the consequences causing the symptoms.
[0130] The term "effects of a de-addiction treatment" in the context of this invention is understood as including any
side effect coming with any de-addiction treatment, especially any kind of withdrawal syndrome.
[0131] The term "ameliorate" in the context of this invention is understood as meaning any improvement on the situation
of the patient treated - either subjectively (feeling of or on the patient) or objectively (measured parameters).
[0132] Further embodiments of the compounds of the invention are described below in the examples. It is evident for
the skilled person that many variations and configurations are possible and can be obtained at will depending on the
compounds selected as starting materials, the relative configurations of the functional groups present, the presence or
not of chiral centers, and on the combination of reactions that are applied. The present invention encompasses all such
variations (enantiomers and diastereoisomers) and possibilities.
EXAMPLES
General Methods and Materials
[0133] All reactions described below were carried out under argon atmosphere unless otherwise noted. The solvents
used were distilled and dried under argon atmosphere before use. All starting materials were purchased commercially
(Aldrich, Acros and Scharlau) and used without further purification. TLC was carried out on silica gel Merck (Kieselgel
60F-254).
[0134] 1H-RMN spectra were measured on Varian Mercury Plus 400MHz with (CH3)4Si as an internal reference and
CD3OD as solvent unless otherwise noted. Spectral data are reported in parts per million (δ) relative to residual signal
of the solvent.
Allodynia Lowered threshold Stimulus and response mode differ
Hyperalgesia Increased response Stimulus and response rate are the same
Hyperpathia Raised threshold; Increased response Stimulus and response rate may be the same or different
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[0135] Mass spectra (DECAXP, ThermoFinnigan) were recorded in ES+ mode and with a direct inlet system (Ammo-
nium Acetate, 10mM Acetonitrile).
EXAMPLE 1: Synthesis of compounds of formula II and IV
Preparation of 6,11 -O-isopropylidene-4,9-anhydrotetrodotoxin-hydrochloride (2) and 6,11-O-isopropylidene-
4,9-anhydrotetrodotoxin-hydrochloride (3)
[0136]
[0137] A solution of acetone (14.3 ml, 194.68 mmol), methanol (40.14 Pl, 0.990 mmol) and acetyl chloride (70.32 Pl,
0.988 mmol) was stirred at room temperature for 30 min. After this time, was added TTX (50 mg, 0.157 mmol). The
suspension was stirred for extra 8 days. Then, it was filtered by means of a cold finger condenser to give TTX as a solid
white (12 mg, 24%). To the resulting solution, diethyl ether (10 ml) was added and a white precipitate was formed; which
was filtered to give a mixture of 6,1 1-O-isopropylidene-4,9-anhydrotetrodotoxin-hydrochloride (2) and 6,11-O-isopro-
pylidene- 4,9- anhydrotetrodotoxin-hydrochloride (3) (9mg, 5% (2) and 11% (3)) as white solids ([2: 3] = 1:2). Then, the
volume of the new resulting solution was reduced to 10 ml and, again, diethyl ether (10 ml) was added. The new precipitate
formed was filtrated to give a mixture of 6,11-O-isopropylidene-4,9-anhydrotetrodotoxin-hydrochloride (2) and 6,11-O-iso-
propylidene-4,9- anhydrotetrodotoxin-hydrochloride (3) (10mg, 6% (2) and 12% (3)) as white solid ([2: 3] = 1: 2). The
volume of the resting solution was reduced to 10 ml and, again, diethyl ether (10 ml) was added. The new precipitate
formed was filtrated to give a mixture of 6,11-O-isopropylidene-4,9-anhydrotetrodotoxin-hydrochloride (2) and 6,11-O-iso-
propylidene-4,9- anhydrotetrodotoxin-hydrochloride (3) (10mg, 6% (2) and 12% (3)) as a white solid ([2: 3] = 1: 2). At the
end, the resting solution was concentrated under reduced pressure to give a mixture of 6,11-O-isopropylidene-4,9-
anhydrotetrodotoxin-hydrochloride (2) and 6,11-O-isopropylidene-4,9-anhydrotetrodotoxin-hydrochloride (3) (10 mg,
5% (2) and 12% (3)) as a brown solid ([2: 3] = 1: 2).
Analytic Description of the Mixture of 6,11-O-isopropylidene- 4,9-anhydrotetrodotoxin hydrochloride (2) and 6,11-O-iso-
propylidene- 4,9-anhydrotetrodotoxin-hydrochloride (3) ([2:3] = 1:2)
[0138]
A) HPLC chromatogram of an aliquot (time 8 days) of the preparation reaction of compounds 2 and 3 is described
in figure 1. The arrows show the peaks assigned to compounds 2 and 3 (ratio [2: 3] = 0.46) by means of their
corresponding mass spectra (see General Methods and Materials).
B) 1H-RMN (Methanol-d4) spectrum of a mixture of compounds 2 and 3 is described in figure 2 (ratio [2: 3], aprox.
0.5; ratio calculated by the proportion of the integrals corresponding to H (4) for compounds 2 and 3, respectively).
Keys: #, signal assigned to H(4) of compound 2; *, signal assigned to H (4) of compound 3.
C) Mass spectrum of a mixture of compounds 2 and 3 is described in figure 3 (ratio [2: 3], aprox. 0.5; determinated
from 1H-RMN and HPLC). The arrows show the peaks assigned to compounds 2 and 3.
Temporal set of the reaction
[0139] A further experiment was performed in order to determine the time sequence of the reaction. Aliquots during
the reaction described above where collected and analyzed by HPLC. (The arrows show the peaks assigned to com-
pounds 2 and 3 supported by their corresponding mass spectra). The following aliquots where collected (the HPLC in
each case are shown in the figures indicated): 
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a) time 26h (t1). See Figure 4.
b) time 144h (t2). See Figure 5.
c) time 192h (t3). See Figure 6.
EXAMPLE 2: Synthesis of a compound of formula III 4-O-Methyl-6,11-O-isopropylidenetetrodotoxin- hydrochlo-
ride (4)
[0140]
[0141] To a mixture of acetone (10 ml) and methanol (17.5 ml), acetyl chloride (423mg, 5.445 mmol) was added. The
solution was stirred for 30 min. After this time, tetrodotoxin (105.20 mg, 0.330 mmol) was added at room temperature.
The solution was stirred for 16h and, then, was concentrated under reduced pressure. To the resulting solution, methanol
(2x 10 ml) was added and, again, concentrated under reduced pressure. Then, methanol (4ml) was added until the
crude solid was completely dissolved. Diethyl ether (10 ml) was added and a white precipitate was formed. The suspension
was filtrated by means of a cold finger condenser to give a 4-O-Methyl- 6,11-O-isopropylidenetetrodotoxin-hydrochloride
(4)(50 mg, 45 %) as a white solid.
Analytic Description of 4-O-Methyl- 6,11-O-isopropylidenetetrodotoxin- hydrochloride (4)
[0142]
A) 1H-RMN (Methanol-d4) spectrum of compound 4 is described in figure 7.
B) Mass spectrum of compound 4 is described in figure 8 (see General Methods and Materials).
Temporal set of the reaction
[0143] A further experiment was performed in order to determine the time sequence of the reaction. Aliquots during
the reaction described above where collected and analyzed by HPLC. (The arrows show the peaks assigned to com-
pounds 1 (TTX), 2, 3 and 4 supported by their corresponding mass spectra). The following aliquots where collected (the
HPLC in each case are shown in the figures indicated):
a) time 7h (t1). See Figure 9.
b) time 120h (t2). See Figure 10.
c) time 168h (t3). See Figure 11.
d) time 216h (t4). See Figure 12.
e) time 888h (t5). See Figure 13.
Claims
1. A process for the synthesis of a compound of formula II:
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wherein
R1 is selected from the group consisting of -H, -OH, -OC (=O) Ra, -ORa, alkyl, -NH2, -NHRb and -NRbRc, wherein
Ra, Rb and Rc are independently selected from an alkyl group;
R2 and R3 are independently selected from the group consisting of -H, -OH and- OC(=O) Ra, -ORb, wherein Ra
and Rb are as previously defined;
R4 and R5 are independently selected from the group consisting of -H and amino protecting group;
R6 is selected from the group consisting of -H, a negative charge and a hydroxyl protecting group;
W is selected from the group consisting of NH, ⊕NH2, O and S; and
Z is selected from the group consisting of
(R7)(R8)C< wherein R7 and R8 are each independently selected from the group consisting of alkyl, cycloalkyl,
alkenyl, cycloalkenyl, alcoxyl, heterocyclyl, aryl and aralkyl; or R7 and R8 together form a group selected
from the group consisting of cycloalkyl, heterocyclyl and cycloalkenyl; and (R9)B<, wherein R9 is selected
from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocyclyl, aryl and aralkyl;
or its salts, in particular pharmaceutically acceptable salts, or tautomers, solvates or enantiomers thereof; 
comprising the step of reacting a compound of formula I
wherein
R1, R2, R3, R4, R5, R6 and W are as defined in formula II;
with a carbonyl or boron reagent selected from the group consisting of
- a carbonyl containing molecule of formula (R7)(R8)C=O or its hydrates or alkyl or aryl acetals or hemiacetals,
wherein R7 and R8 are as previously defined;
- a boron derivative of formula R9B(OR10)2, wherein R10 are both independently selected from the group con-
sisting of -H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocyclyl, aryl and aralkyl;
- a boron derivative of formula R9B=O; and
- a boron derivative of formula
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wherein R9 is as defined above;
in the presence of a substantially anhydrous acid solution which has been generated in situ.
2. Process according to claim 1 wherein the generation of the acid comprises contacting an alcohol with an acid
precursor.
3. Process according to claim 2, wherein said alcohol is an alcohol of formula R11OH, wherein R11 is selected from
the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocyclyl, aryl and aralkyl.
4. Process according to any of claims 2 and 3, wherein R11 is alkyl, preferably a C1-C6 alkyl.
5. Process according to any of claims 2 to 4, wherein said acid precursor is selected from the group consisting of
- an acyl halide of formula R12COX, wherein
X is selected from the group consisting of F, Cl, Br or I; and
R12 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocyclyl, aryl and
aralkyl;
- an acid anhydride of formula R12C(=O)O(O=)CR12, wherein each of R12 can be the same or different as
defined above; and
- an acid anhydride of formula R13(O=)2SOS (=O)2R13, wherein each of R13 are independently selected from
the group consisting of alkyl, preferably halogen substituted alkyl, aryl and aralkyl.
6. Process according to claim 5, wherein R12 is alkyl, preferably a C1-C6 alkyl.
7. Process according to claim 5, wherein R13 is -CF3 or p- tolyl.
8. Process according to any of the previous claims, wherein R1, R2 and R3 are -OH.
9. Process according to any of claims 1-8, wherein R1, R2 and R3 are independently selected from -H or -OAc.
10. Process according to any of the previous claims, wherein the reaction time is less than 100 hours, preferably less
than 50 hours, more preferably less than 40 hours, more preferably less than 30 hours, more preferably less than
25 hours.
11. Process according to any of claims 2 to 10, wherein said alcohol is in excess with regard to said acid precursor.
12. Process according to any of claims 2 to 10, wherein said alcohol and said acid precursor are in equimolar ratio.
13. Process according to any of the previous claims, wherein the compound of formula (R7)(R8)C=O is selected from
the group consisting of formaldehyde, acetaldehyde, 2,2-dimethylpropylaldehyde, 3,3-dimethylbutirylaldehyde, 3,3-
dimethyl- 2- butanone, 4’- methoxyacetophenone, acrolein, acetone, ethyl acetate, methyl acetate, ethyl formate,
methyl formate and 3H-Isobenzofuran-1-one, or the hydrates or alkyl or aryl acetals or hemiacetals thereof.
14. Process according to any of claims I to 12, wherein the compound of formula R9B=O is selected from the group
consisting of butylboronic acid and phenylboronic acid.
15. Process according to claim 13, wherein the compound of formula (R7)(R8)C=O is acetone.
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16. Process for the synthesis of a compound of formula III
wherein
R2, R4, R5 and Z are as defined in claim 1;
R1 is alcoxyl; and
W is selected from the group consisting of -NH, O and S;
or its salts, in particular pharmaceutically acceptable salts, or tautomers, solvates or enantiomers thereof; 
comprising the step of reacting a compound of formula I, wherein R3 is -OH, with a carbonyl or boron reagent of
formula (R7)(R8)C=O or of formula R9B(OR10)2, or of formula R9B=O or of formula
wherein the compound of formula I and the carbonyl or boron reagent are as defined in claim 1 in the presence of
a substantially anhydrous acid solution which has been generated in situ and an alcohol, said alcohol being in excess
with regard to the carbonyl or boron reagent.
17. Process according to claim 16, wherein said alcohol is an alcohol of formula R11OH, wherein R11 is selected from
alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocyclyl, aryl and aralkyl.
18. Process according to claim 16, wherein R1 is -OR11, wherein R11 is as defined in claim 15, preferably C1-C6 alkyl.
19. Process for the synthesis of a compound of formula IV
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wherein
R2, R4, R5, R6 and Z are as defined in claim 1; and
W is selected from the group consisting of -NH, O and S;
or its salts, in particular pharmaceutically acceptable salts, or tautomers, solvates or enantiomers thereof; 
comprising the step of reacting a compound of formula I, wherein R3 is -OH, with a carbonyl or boron reagent of
formula (R7)(R8)C=O or of formula R9B(OR10)2 or of formula R9B=O or of formula
wherein the compound of formula I and the carbonyl or boron reagent are as defined in claim 1, in the presence of
a substantially anhydrous acid solution which has been generated in situ, said alcohol being in equimolar ratio with
regard to the carbonyl or boron reagent.
20. Process according to any of claims 16 to 19, wherein the compound is in the form of a salt, preferably a salt of and
acid selected from the group consisting of XH, R12C(=O) OH and R13(O=)2SOH, wherein X, R12 and R13 are as
defined in claim 5.
21. Process according to any of claims 19 to 20 wherein the compound of formula IV is further transformed into a
compound of formula III, by further contacting said compound of formula IV with an alcohol.
22. Process according to any of claims 16 to 20 wherein the reaction time is more than 5 hours, preferably more than
10 hours, more preferably more than 20 hours, more preferably more than 50 hours, more preferably more than
100 hours.
23. A compound of formula II as defined in claim 1 or its tautomers or enantiomers or solvates or salts or mixtures thereof.
24. A compound according to claim 23, wherein R1, R2 and R3 are -OH.
25. A compound of formula III as defined in claim 16 with the proviso it is not 4-O- Methyl-6,11-O- isopropylidenetetro-
dotoxin-hydrochloride.
26. A compound of formula IV as defined in claim 19 with the proviso it is not 6,11-O- isopropylidene-4,9-anhydrotetro-
dotoxin-hydrochloride.
27. A compound according to any of claims 23, 25 or 26 wherein R7 and R8 are both -H, methyl; or R7 is -H and R8 is
selected from the group consisting of methyl, t-butyl, 2,2- dimethylpropyl, vinyl, methoxy and ethoxy; or R7 is methyl
and R8 is selected from the group consisting of t- butyl, 4’- methoxyphenyl, ethoxy or methoxy.
28. A pharmaceutical composition comprising a compound of formula II as defined in claim 23 or a pharmaceutically
acceptable salt or solvate or tautomer or enantiomer thereof, and at least one pharmaceutically acceptable carrier.
29. A pharmaceutical composition comprising a compound of formula III as defined in claim 25, or a pharmaceutically
acceptable salt or solvate or tautomer or enantiomer thereof, and at least one pharmaceutically acceptable carrier.
30. Pharmaceutical composition according to claim 29, as pressurised inhalator, inhalation powder, pre-dispensed
inhalation powder, inhalation vapour or inhalation gas.
31. A pharmaceutical composition comprising a compound of formula IV as defined in claim 26, or a pharmaceutically
acceptable salt or solvate or tautomer or enantiomer thereof, and at least one pharmaceutically acceptable carrier.
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32. Use of a compound of formula II as defined in claim 23 for manufacturing a medicament for the treatment and/or
prophylaxis of pain, especially cancer pain, cancer treatment related pain, moderate to severe pain, and neuropathic
pain; drug abuse and/or drug addiction, medicament abuse and/or medicament addiction, preferably drug abuse
and/or drug addiction; and nicotine addiction.
33. Use of a compound of formula III as defined in claim 25 for manufacturing a medicament for the treatment and/or
prophylaxis of pain, especially cancer pain, cancer treatment related pain, moderate to severe pain, and neuropathic
pain; drug abuse and/or drug addiction, medicament abuse and/or medicament addiction, preferably drug abuse
and/or drug addiction; and nicotine addiction.
34. Use of a compound of formula IV as defined in claim 26 for manufacturing a medicament for the treatment and/or
prophylaxis of pain, especially cancer pain, cancer treatment related pain, moderate to severe pain, and neuropathic
pain; drug abuse and/or drug addiction, medicament abuse and/or medicament addiction, preferably drug abuse
and/or drug addiction; and nicotine addiction.
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